Search results
Results from the WOW.Com Content Network
“Early onset colorectal cancer (colon cancer in persons under age 50) is on the rise, but in absolute numbers, the risk is low. So there are a lot of people at risk, but very few will develop ...
The site began in 1998 as a pen and paper questionnaire called the Harvard Cancer Risk Index. [2] In January 2000, The Harvard Cancer Risk Index developed into an online assessment and was renamed Your Cancer Risk, and offered assessments for four cancers: breast, colon, lung, and prostate. Six months later, eight additional cancers were added. [3]
People older than 50 are still at a greater risk of developing colon cancer overall. However, people under 50 are more often diagnosed with hard-to-treat, advanced forms of the disease.
Researchers say chronic inflammation raises a person’s risk of developing colorectal cancer as well as suppresses the body’s ability to fight the disease. The Western diet, which is high in ...
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). [5] Signs and symptoms may include blood in the stool , a change in bowel movements , weight loss, abdominal pain and fatigue. [ 9 ]
Advertisement for a healthy diet to possibly reduce cancer risk. An average 35% of human cancer mortality is attributed to the diet of the individual. [10] Studies have linked excessive consumption of red or processed meat to an increased risk of breast cancer, colon cancer, and pancreatic cancer, a phenomenon which could be due to the presence of carcinogens in meats cooked at high temperatures.
A new study in Gut found that colon cancer tumors have an imbalance of inflammatory and anti-inflammatory lipids, which suggests that chronic inflammation could raise the risk of colorectal cancer.
The Oncotype DX Colon Cancer Assay is a genomic test for patients with newly diagnosed stage II colon cancer, launched in January 2010 by Genomic Health. The test is a validated diagnostic assay based on an individual patient's colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following ...